相关实验视频
Updated: Sep 18, 2025

04:52
A Modified Technique for Transverse Aortic Constriction in Mice
Published on: August 18, 2022
4.9K
与多个系统缩中的心血管自主性衰竭相关的结构性改变
Claire Georges1,2, Germain Arribarat3, Marc Kermorgant2,4
1CH Montauban, Service de Neurologie, Montauban, France.
European journal of neurology
|June 25, 2025
概括
多重系统缩 (MSA) 中的自主性衰竭与大脑干和小脑缩有关. 图像检测显示,脑髓和小脑退化与心血管自主功能障碍严重程度相关.
科学领域:
- 神经成像是一种神经成像.
- 神经学 神经学
- 自主性功能障碍 自主性功能障碍
背景情况:
- 在多个系统缩 (MSA) 中,早期自主性衰竭 (AF) 预测生存率不佳.
- 尸检研究将AF与大脑干和脊髓中的前质自主神经元退化联系起来.
研究的目的:
- 在MSA患者的心血管AF相关的大脑成像上表征大脑变化.
- 研究大脑结构和自主功能障碍之间的关系.
主要方法:
- 通过正静性低血压 (OH) 和心率 (HR) 的变化来评估心血管自主功能.
- 基于voxel的形态测量 (SPM12) 和FreeSurfer 7.0用于灰色物质 (GM) 缩分析.
- 多变量分析根据年龄,疾病严重程度 (UMSARS) 和内体积进行调整.
主要成果:
- 骨髓缩与OH相关 (p < 0.006).骨髓缩与OH相关 (p < 0.006).
- 大脑小脑的转基因损失 (左前小脑,左插入核,右牙) 与血压变化 (ΔDBP, ΔSBP) 相关,并降低了HR可变性.
- 包括62名MSA患者 (平均年龄为67.3岁).
结论:
- 脑髓体积与正静性低血压有很强的相关性.
- 小脑退化与MSA心血管自主性衰竭的严重程度有关.
相关概念视频
Pathophysiology of Heart Failure
1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Disorders of the Autonomic Nervous System
833
The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's...
Raynaud's disease, also known as Raynaud's...
833
Heart Failure II: Pathophysiology
59
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
59
Cardiomyopathy III: Hypertrophic Cardiomyopathy
65
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
65
Cardiomyopathy I: Introduction and Classification
72
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
72
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524

